Target Ovarian Cancer is supporting a research project that will test how well a new class of drug can treat a less common type of ovarian cancer.

In July 2023 Christine was told that her diagnosis had become life limited. However, thanks to access to a new drug, bevacizumab, she has been stable since May 2024.

Previously diagnosed with diverticulitis, 68-year-old Georgina assumed her abdominal pain was related. When her symptoms changed, she visited her GP and in March 2022 was diagnosed with stage 3 ovarian cancer, with a CA-125 level of 1,800.

Led by Dr Jun Ishihara at Imperial College London, this three-year project will test a new and original immunotherapy (CBD-IL-12) for low grade serous ovarian cancer.

We're welcoming Professor Fiona Thistlethwaite, the Medical Director of The Christie Clinical Research Facility, as the new Chair of our Scientific Advisory Board (SAB).

Celebrate how the achievements of our research programme last year (July 2022 – June 2023) are taking us one step closer to improving access to treatments for all.

Led by Professor James Brenton, this project explored the immune system and its potential to transform ovarian cancer treatments by learning more about high-grade serous ovarian cancer (HGSOC) tumours. 

Target Ovarian Cancer’s Research Manager, Emma Dennett, writes about the importance of publications and how they can be used as an early indication of the impact of our ovarian cancer research.

Led by Professor Charlie Gourley and Dr Robb Hollis, this project set out to understand more about the biology of low grade serous ovarian cancer in order to find new treatment options. 

A new research project awarded funding from Target Ovarian Cancer is exploring immunotherapy for high grade serous ovarian cancer.

Progress in ovarian cancer is possible, if urgent action is taken. That’s why the announcement of a new study to pilot use of an advanced blood test for ovarian cancer is encouraging for the ovarian cancer community.  

Led by Professor Richard Edmondson, this project set out to define the DNA damage response defects in high grade serous ovarian cancer (HGSOC) to predict patients' response to chemotherapy and the likelihood of recurrence.